{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:40:54Z","timestamp":1790185254149,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10072-025-08218-3","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:15:19Z","timestamp":1746846919000},"page":"4293-4307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pro-inflammatory cytokines in myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7125-6425","authenticated-orcid":false,"given":"Ali","family":"Shushtari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-9810","authenticated-orcid":false,"given":"Hamidreza","family":"Ashayeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-430X","authenticated-orcid":false,"given":"Amirhossein","family":"Salmannezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-9332","authenticated-orcid":false,"given":"Homa","family":"Seyedmirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"11","key":"8218_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia Gravis: epidemiology, pathophysiology and clinical manifestations, (in eng). J Clin Med 10(11):21. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"issue":"10","key":"8218_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia Gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"1","key":"8218_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N et al (2021) Global prevalence of myasthenia Gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Translational Med 19(1):1\u201323","journal-title":"J Translational Med"},{"key":"8218_CR4","doi-asserted-by":"publisher","unstructured":"Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2015) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases, (in eng), Cytokine, vol. 74, no. 1, pp. 5\u201317, Jul https:\/\/doi.org\/10.1016\/j.cyto.2014.09.011","DOI":"10.1016\/j.cyto.2014.09.011"},{"issue":"3","key":"8218_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A et al (2021) Roles of cytokines and T cells in the pathogenesis of myasthenia Gravis. Clin Experimental Immunol 203(3):366\u2013374","journal-title":"Clin Experimental Immunol"},{"key":"8218_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","volume":"52","author":"A Gradolatto","year":"2014","unstructured":"Gradolatto A et al (2014) Both Treg cells and Tconv cells are defective in the myasthenia Gravis thymus: roles of IL-17 and TNF-\u03b1. J Autoimmun 52:53\u201363","journal-title":"J Autoimmun"},{"issue":"9","key":"8218_CR7","doi-asserted-by":"publisher","first-page":"102617","DOI":"10.1016\/j.autrev.2020.102617","volume":"19","author":"P Migliorini","year":"2020","unstructured":"Migliorini P, Italiani P, Pratesi F, Puxeddu I, Boraschi D (2020) The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmun Rev 19(9):102617","journal-title":"Autoimmun Rev"},{"issue":"5","key":"8218_CR8","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"D-i Jang","year":"2021","unstructured":"Jang D-i et al (2021) The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci 22(5):2719","journal-title":"Int J Mol Sci"},{"key":"8218_CR9","doi-asserted-by":"publisher","unstructured":"Li X, Xiao BG, Xi JY, Lu CZ, Lu JH (Feb 2008) Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia Gravis, (in eng). Clin Immunol 126(2):180\u2013188. https:\/\/doi.org\/10.1016\/j.clim.2007.10.001","DOI":"10.1016\/j.clim.2007.10.001"},{"issue":"3","key":"8218_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10072-009-0023-0","volume":"30","author":"JS Lee","year":"2009","unstructured":"Lee JS, Joo IS, Seok JI (2009) Widely varying TNF-\u03b1 levels in patients with myasthenia Gravis, (in English). Neurol Sci Article Vol 30(3):259\u2013262. https:\/\/doi.org\/10.1007\/s10072-009-0023-0","journal-title":"Neurol Sci Article Vol"},{"key":"8218_CR11","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"8218_CR12","unstructured":"Wells G et al (2000) The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis, \u115f, vol. \u115f, 01\/01"},{"key":"8218_CR13","doi-asserted-by":"publisher","unstructured":"Lo CK, Mertz D, Loeb M (2014) Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments, (in eng), BMC Med Res Methodol, vol. 14, p. 45, Apr 1 https:\/\/doi.org\/10.1186\/1471-2288-14-45","DOI":"10.1186\/1471-2288-14-45"},{"key":"8218_CR14","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2008) Analysing Data and Undertaking Meta-Analyses, in Cochrane Handbook for Systematic Reviews of Interventions, pp. 243\u2013296","DOI":"10.1002\/9780470712184.ch9"},{"key":"8218_CR15","doi-asserted-by":"publisher","unstructured":"Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range, (in eng), Stat Methods Med Res, vol. 27, no. 6, pp. 1785\u20131805, Jun https:\/\/doi.org\/10.1177\/0962280216669183","DOI":"10.1177\/0962280216669183"},{"key":"8218_CR16","doi-asserted-by":"publisher","unstructured":"Wan X, Wang W, Liu J, Tong T Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range, BMC Medical Research Methodology, vol. 14, no. 1, p. 135, 2014\/12\/19 2014. https:\/\/doi.org\/10.1186\/1471-2288-14-135","DOI":"10.1186\/1471-2288-14-135"},{"key":"8218_CR17","doi-asserted-by":"publisher","unstructured":"Confalonieri P, Antozzi C, Cornelio F, Simoncini O, Mantegazza R (1993) Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon-\u03b3 and tumor necrosis factor-\u03b1 levels in patients\u2019 serum, (in English), J. NEUROIMMUNOL., Article vol. 48, no. 1, pp. 33\u201336. https:\/\/doi.org\/10.1016\/0165-5728(93)90055-4","DOI":"10.1016\/0165-5728(93)90055-4"},{"key":"8218_CR18","doi-asserted-by":"publisher","unstructured":"Jander S, Stoll G (2002) Increased serum levels of the interferon-\u03b3-inducing cytokine interleukin-18 in myasthenia gravis, (in English), Neurology, Article vol. 59, no. 2, pp. 287\u2013289. https:\/\/doi.org\/10.1212\/WNL.59.2.287","DOI":"10.1212\/WNL.59.2.287"},{"issue":"11","key":"8218_CR19","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/00207450601125840","volume":"117","author":"Z Yapici","year":"2007","unstructured":"Yapici Z, T\u00fcz\u00fcn E, Altunayo\u01e7lu V, Erdo\u01e7an A, Eraksoy M (2007) High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia Gravis, (in English). Int J Neurosci Article Vol 117(11):1505\u20131512. https:\/\/doi.org\/10.1080\/00207450601125840","journal-title":"Int J Neurosci Article Vol"},{"key":"8218_CR20","doi-asserted-by":"publisher","unstructured":"Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC (2009) Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis, (in English), Eur. J. Neurol., Article vol. 16, no. 12, pp. 1318\u20131322. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02729.x","DOI":"10.1111\/j.1468-1331.2009.02729.x"},{"key":"8218_CR21","doi-asserted-by":"publisher","unstructured":"Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S (2014) Serum cytokine and chemokine profiles in patients with myasthenia gravis, (in English), CLIN. EXP. IMMUNOL., Article vol. 176, no. 2, pp. 232\u2013237. https:\/\/doi.org\/10.1111\/cei.12272","DOI":"10.1111\/cei.12272"},{"key":"8218_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.12.015","volume":"315","author":"IM Rozmilowska","year":"2018","unstructured":"Rozmilowska IM, Adamczyk-Sowa MH (2018) What is the role of Interleukin 33 and ST2 receptor in myasthenia Gravis?? (in English). J NEUROIMMUNOL Article Vol 315:50\u201357. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.015","journal-title":"J NEUROIMMUNOL Article Vol"},{"key":"8218_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jocn.2019.02.012","volume":"63","author":"Z Wang","year":"2019","unstructured":"Wang Z, Wang W, Chen Y, Xu S, Wei D, Huang X (2019) Elevated expression of interleukin-33 in myasthenia Gravis patients, (in English). J Clin Neurosci Article Vol 63:32\u201336. https:\/\/doi.org\/10.1016\/j.jocn.2019.02.012","journal-title":"J Clin Neurosci Article Vol"},{"key":"8218_CR24","doi-asserted-by":"publisher","unstructured":"Hu Y et al (2020) Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis, (in English), Int. Immunopharmacol., Article vol. 80, Art no. 106130. https:\/\/doi.org\/10.1016\/j.intimp.2019.106130","DOI":"10.1016\/j.intimp.2019.106130"},{"key":"8218_CR25","doi-asserted-by":"publisher","unstructured":"Meng H et al (2021) FoxP3\u2013\u2009Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines, (in English), Front. Neurol., Article vol. 12, Art no. 755356. https:\/\/doi.org\/10.3389\/fneur.2021.755356","DOI":"10.3389\/fneur.2021.755356"},{"key":"8218_CR26","doi-asserted-by":"publisher","unstructured":"Huang P (2023) The relationship between serum iron levels and AChR-Ab and IL-6 in patients with myasthenia gravis, (in English), European Review for Medical and Pharmacological Sciences, Article vol. 27, no. 1, pp. 98\u2013102. https:\/\/doi.org\/10.26355\/eurrev_202301_30857","DOI":"10.26355\/eurrev_202301_30857"},{"issue":"5","key":"8218_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3988\/jcn.2022.0265","volume":"19","author":"JW Seok","year":"2023","unstructured":"Seok JW, Lee J, Kim M, Kim MJ, Shin HY, Kim SW (2023) Plasma myokine profiles in patients with AChR-and MuSK-Ab-Positive myasthenia Gravis, (in English). J Clin Neurol Article Vol 19(5):469\u2013477. https:\/\/doi.org\/10.3988\/jcn.2022.0265","journal-title":"J Clin Neurol Article Vol"},{"key":"8218_CR28","doi-asserted-by":"publisher","unstructured":"Yasuda M et al (2023) Serum cytokine profiles in myasthenia Gravis with anti-muscle-specific kinase antibodies, (in English). J Neuroimmunol Article Vol 384. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578205","DOI":"10.1016\/j.jneuroim.2023.578205"},{"key":"8218_CR29","doi-asserted-by":"publisher","unstructured":"Wei SL et al (2024) Altered serum levels of cytokines in patients with myasthenia gravis, (in eng), Heliyon, vol. 10, no. 1, p. e23745, Jan 15 https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23745","DOI":"10.1016\/j.heliyon.2023.e23745"},{"key":"8218_CR30","unstructured":"Varghese N et al Th17 pathway-related immune signatures in the pathobiology of myasthenia Gravis: integrating the roles of regulatory\/effector cytokines and transcription factors. Clin Exp Neuroimmunol"},{"issue":"1","key":"8218_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","volume":"76","author":"Z Wang","year":"2012","unstructured":"Wang Z, Wang W, Chen Y, Wei D (2012) T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol 76(1):54\u201361","journal-title":"Scand J Immunol"},{"key":"8218_CR32","doi-asserted-by":"publisher","first-page":"106130","DOI":"10.1016\/j.intimp.2019.106130","volume":"80","author":"Y Hu","year":"2020","unstructured":"Hu Y et al (2020) Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia Gravis. Int Immunopharmacol 80:106130","journal-title":"Int Immunopharmacol"},{"key":"8218_CR33","doi-asserted-by":"crossref","unstructured":"Wei S-L et al (2024) Altered serum levels of cytokines in patients with myasthenia gravis, Heliyon, vol. 10, no. 1","DOI":"10.1016\/j.heliyon.2023.e23745"},{"key":"8218_CR34","doi-asserted-by":"crossref","unstructured":"Jander S, Stoll G (2002) Increased serum levels of the interferon-\u03b3\u2013inducing cytokine interleukin-18 in myasthenia gravis, Neurology, vol. 59, no. 2, pp. 287\u2013289","DOI":"10.1212\/WNL.59.2.287"},{"key":"8218_CR35","doi-asserted-by":"publisher","first-page":"755356","DOI":"10.3389\/fneur.2021.755356","volume":"12","author":"H Meng","year":"2021","unstructured":"Meng H et al (2021) FoxP3\u2013\u2009Tr1 cell in generalized myasthenia Gravis and its relationship with the Anti-AChR antibody and Immunomodulatory cytokines. Front Neurol 12:755356","journal-title":"Front Neurol"},{"key":"8218_CR36","doi-asserted-by":"publisher","first-page":"578205","DOI":"10.1016\/j.jneuroim.2023.578205","volume":"384","author":"M Yasuda","year":"2023","unstructured":"Yasuda M et al (2023) Serum cytokine profiles in myasthenia Gravis with anti-muscle-specific kinase antibodies. J NEUROIMMUNOL 384:578205","journal-title":"J NEUROIMMUNOL"},{"key":"8218_CR37","first-page":"98","volume":"27","author":"P Huang","year":"2023","unstructured":"Huang P (2023) The relationship between serum iron levels and AChR-Ab and IL-6 in patients with myasthenia Gravis. Eur Rev Med Pharmacol Sci 27:98\u2013102","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"8218_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3988\/jcn.2022.0265","volume":"19","author":"JW Seok","year":"2023","unstructured":"Seok JW, Lee J, Kim M, Kim MJ, Shin HY, Kim SW (2023) Plasma myokine profiles in patients with AChR-and MuSK-Ab-Positive myasthenia Gravis. J Clin Neurol (Seoul Korea) 19(5):469","journal-title":"J Clin Neurol (Seoul Korea)"},{"key":"8218_CR39","doi-asserted-by":"publisher","unstructured":"Yapici Z, T\u00fcz\u00fcn E, Altunayo\u011flu V, Erdo\u011fan A, Eraksoy M (Nov 2007) High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia Gravis, (in eng). Int J Neurosci 117(11):1505\u20131512. https:\/\/doi.org\/10.1080\/00207450601125840","DOI":"10.1080\/00207450601125840"},{"issue":"2","key":"8218_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cei.12272","volume":"176","author":"A Uzawa","year":"2014","unstructured":"Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S (2014) Serum cytokine and chemokine profiles in patients with myasthenia Gravis. Clin Experimental Immunol 176(2):232\u2013237","journal-title":"Clin Experimental Immunol"},{"key":"8218_CR41","doi-asserted-by":"publisher","unstructured":"Payet CA, You A, Fayet OM, Dragin N, Berrih-Aknin S, Le R, Panse (2022) Myasthenia Gravis: An Acquired Interferonopathy? (in English), Cells, Review vol. 11, no. 7, Art no. 1218. https:\/\/doi.org\/10.3390\/cells11071218","DOI":"10.3390\/cells11071218"},{"key":"8218_CR42","doi-asserted-by":"publisher","unstructured":"Ross SH, Cantrell DA (2018) Signaling and Function of Interleukin-2 in T Lymphocytes, (in eng), Annu Rev Immunol, vol. 36, pp. 411\u2013433, Apr 26 https:\/\/doi.org\/10.1146\/annurev-immunol-042617-053352","DOI":"10.1146\/annurev-immunol-042617-053352"},{"key":"8218_CR43","doi-asserted-by":"publisher","unstructured":"Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB (Jul-Sep 2019) Inflammation and cancer, (in eng). Ann Afr Med 18(3):121\u2013126. https:\/\/doi.org\/10.4103\/aam.aam_56_18","DOI":"10.4103\/aam.aam_56_18"},{"key":"8218_CR44","doi-asserted-by":"publisher","unstructured":"Romi F (2011) Thymoma in myasthenia gravis: from diagnosis to treatment, (in eng), Autoimmune Dis, vol. p. 474512, 2011. https:\/\/doi.org\/10.4061\/2011\/474512","DOI":"10.4061\/2011\/474512"},{"key":"8218_CR45","doi-asserted-by":"publisher","first-page":"919973","DOI":"10.3389\/fimmu.2022.919973","volume":"13","author":"SA Ihim","year":"2022","unstructured":"Ihim SA et al (2022) Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front Immunol 13:919973. https:\/\/doi.org\/10.3389\/fimmu.2022.919973. (in eng)","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"8218_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jneuroim.2004.04.021","volume":"156","author":"SB Adikari","year":"2004","unstructured":"Adikari SB, Lefvert AK, Pirskanen R, Press R, Link H, Huang Y-M (2004) Dendritic cells activate autologous T cells and induce IL-4 and IL-10 production in myasthenia Gravis. J Neuroimmunol 156(1\u20132):163\u2013170","journal-title":"J Neuroimmunol"},{"key":"8218_CR47","doi-asserted-by":"publisher","unstructured":"Song Y et al (2023) Aberrant dendritic cell subsets in patients with myasthenia Gravis and related clinical features, (in eng). Neuroimmunomodulation Feb 13. https:\/\/doi.org\/10.1159\/000529626","DOI":"10.1159\/000529626"},{"key":"8218_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fimmu.2018.00763","volume":"9","author":"K Nakanishi","year":"2018","unstructured":"Nakanishi K (2018) Unique action of interleukin-18 on T cells and other immune cells. Front Immunol 9:763","journal-title":"Front Immunol"},{"key":"8218_CR49","doi-asserted-by":"crossref","unstructured":"Link J et al (1994) Organ-specific autoantigens induce interferon\u2010\u03b3 and interleukin\u20104 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis, Neurology, vol. 44, no. 4, pp. 728\u2013728","DOI":"10.1212\/WNL.44.4.728"},{"issue":"12","key":"8218_CR50","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1096\/fj.01-0072com","volume":"15","author":"SH Im","year":"2001","unstructured":"Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, Fuchs S (2001) Suppression of experimental myasthenia Gravis, a B cell-mediated autoimmune disease, by Blockade of IL\u201018. FASEB J 15(12):2140\u20132148","journal-title":"FASEB J"},{"key":"8218_CR51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","volume":"8","author":"B Griesenauer","year":"2017","unstructured":"Griesenauer B, Paczesny S (2017) The ST2\/IL-33 axis in immune cells during inflammatory diseases. Front Immunol 8:475","journal-title":"Front Immunol"},{"key":"8218_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-9255-8-22","volume":"8","author":"AM Miller","year":"2011","unstructured":"Miller AM (2011) Role of IL-33 in inflammation and disease. J Inflamm 8:1\u201312","journal-title":"J Inflamm"},{"issue":"6","key":"8218_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.smim.2013.10.006","volume":"25","author":"MU Martin","year":"2013","unstructured":"Martin MU (2013) Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol 25(6):449\u2013457. https:\/\/doi.org\/10.1016\/j.smim.2013.10.006. 12\/15\/ 2013, doi","journal-title":"Semin Immunol"},{"issue":"5","key":"8218_CR54","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaci.2009.02.026","volume":"123","author":"MA Rank","year":"2009","unstructured":"Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H (2009) IL-33\u2013activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 123(5):1047\u20131054. https:\/\/doi.org\/10.1016\/j.jaci.2009.02.026. \/05\/01\/ 2009, doi","journal-title":"J Allergy Clin Immunol"},{"key":"8218_CR55","doi-asserted-by":"crossref","unstructured":"Dinarello CA (2005) An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor, Immunity, vol. 23, no. 5, pp. 461\u2013462","DOI":"10.1016\/j.immuni.2005.10.004"},{"key":"8218_CR56","doi-asserted-by":"publisher","unstructured":"Zhou Y et al (Dec 2023) Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia Gravis through targeting macrophages, (in eng). J Control Release 364:458\u2013472. https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.006","DOI":"10.1016\/j.jconrel.2023.11.006"},{"key":"8218_CR57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2017.05.040","volume":"656","author":"C-C Wang","year":"2017","unstructured":"Wang C-C et al (2017) Caspase-1 inhibitor regulates humoral responses in experimental autoimmune myasthenia Gravis via IL-6-dependent inhibiton of STAT3. Neurosci Lett 656:169\u2013176","journal-title":"Neurosci Lett"},{"key":"8218_CR58","doi-asserted-by":"publisher","unstructured":"Wang CC et al (Jun 14 2015) Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia Gravis by innate dendric cell IL-1-IL-17 pathway, (in eng). J Neuroinflammation 12:118. https:\/\/doi.org\/10.1186\/s12974-015-0334-4","DOI":"10.1186\/s12974-015-0334-4"},{"key":"8218_CR59","doi-asserted-by":"publisher","unstructured":"Park S-H, Kim MS, Lim HX, Cho D, Kim TS IL-33-matured dendritic cells promote Th17 cell responses via IL-1\u03b2 and IL-6, Cytokine, vol. 99, pp. 106\u2013113, 2017\/11\/01\/ 2017. https:\/\/doi.org\/10.1016\/j.cyto.2017.07.022","DOI":"10.1016\/j.cyto.2017.07.022"},{"key":"8218_CR60","doi-asserted-by":"publisher","unstructured":"Fuchs S, Aricha R, Reuveni D, Souroujon MC (2014) Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches, (in eng), Journal of autoimmunity, vol. 54, pp. 51\u2013\u20099, Nov https:\/\/doi.org\/10.1016\/j.jaut.2014.06.003","DOI":"10.1016\/j.jaut.2014.06.003"},{"key":"8218_CR61","doi-asserted-by":"publisher","unstructured":"Villegas JA, Van Wassenhove J, Le Panse R, Berrih-Aknin S, Dragin N (2018) An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor\u2013positive myasthenia gravis patients, Annals of the New York Academy of Sciences, vol. 1413, no. 1, pp. 154\u2013162. https:\/\/doi.org\/10.1111\/nyas.13591","DOI":"10.1111\/nyas.13591"},{"key":"8218_CR62","doi-asserted-by":"publisher","unstructured":"Bertolini JN, Benson EM (1990) The role of human interleukin-6 in B-cell isotype regulation and differentiation, (in eng), Cell Immunol, vol. 125, no. 1, pp. 197\u2013209, Jan https:\/\/doi.org\/10.1016\/0008-8749(90)90074-2","DOI":"10.1016\/0008-8749(90)90074-2"},{"issue":"3","key":"8218_CR63","first-page":"1","volume":"7","author":"E Klimova","year":"2016","unstructured":"Klimova E, Bozhkov A, Boyko V, Drozdova L, Lavinskaya E, Skok M (2016) Endogenic cytotoxic factors and formation of the clinic forms of myasthenia. Translational Biomed 7(3):1\u201313","journal-title":"Translational Biomed"},{"issue":"9","key":"8218_CR64","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","volume":"180","author":"KN Couper","year":"2008","unstructured":"Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180(9):5771\u20135777","journal-title":"J Immunol"},{"key":"8218_CR65","doi-asserted-by":"publisher","unstructured":"Blanchard-Rohner G, Pulickal AS, Jol-van der CM, Zijde MD, Snape, Pollard AJ (2009) Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans, Blood, vol. 114, no. 24, pp. 4998\u20135002. https:\/\/doi.org\/10.1182\/blood-2009-03-211052","DOI":"10.1182\/blood-2009-03-211052"},{"issue":"3","key":"8218_CR66","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaut.2005.01.013","volume":"24","author":"E T\u00fcz\u00fcn","year":"2005","unstructured":"T\u00fcz\u00fcn E, Meriggioli MN, Rowin J, Yang H, Christadoss P (2005) Myasthenia Gravis patients with low plasma IL-6 and IFN-\u03b3 benefit from etanercept treatment. J Autoimmun 24(3):261\u2013268 2005\/05\/01\/. https:\/\/doi.org\/10.1016\/j.jaut.2005.01.013","journal-title":"J Autoimmun"},{"key":"8218_CR67","doi-asserted-by":"publisher","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals, (in eng), Drugs, vol. 82, no. 8, pp. 865\u2013887, Jun https:\/\/doi.org\/10.1007\/s40265-022-01726-y","DOI":"10.1007\/s40265-022-01726-y"},{"issue":"4","key":"8218_CR68","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/path.4806","volume":"240","author":"RS Hardy","year":"2016","unstructured":"Hardy RS et al (2016) 11\u03b2-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. J Pathol 240(4):472\u2013483","journal-title":"J Pathol"},{"key":"8218_CR69","doi-asserted-by":"crossref","unstructured":"Ko\u00e7 E, Albayrak F, \u00d6z HE, K\u0131sac\u0131k B, MYASTHENIA GRAVIS AND ANTI-TNF. GOOD NEWS OR BAD NEWS? LONG-TERM FOLLOW-UP (2023) CASE REPORT AND REVIEW OF LITERATURE, A TRIANGLE: RHEUMATOID ARTHRITIS,","DOI":"10.4274\/qrheumatol.galenos.2023.09797"},{"issue":"4","key":"8218_CR70","doi-asserted-by":"publisher","first-page":"e0214857","DOI":"10.1371\/journal.pone.0214857","volume":"14","author":"S Li","year":"2019","unstructured":"Li S et al (2019) Building the drug-GO function network to screen significant candidate drugs for myasthenia Gravis. PLoS ONE 14(4):e0214857","journal-title":"PLoS ONE"},{"issue":"1","key":"8218_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14195","volume":"1452","author":"XJ Cai","year":"2019","unstructured":"Cai XJ et al (2019) Myasthenia Gravis and specific immunotherapy: monoclonal antibodies. Ann N Y Acad Sci 1452(1):18\u201333","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"8218_CR72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/acn3.51312","volume":"8","author":"X Huan","year":"2021","unstructured":"Huan X et al (2021) In-depth peripheral CD4\u2009+\u2009T profile correlates with myasthenic crisis. Ann Clin Transl Neurol 8(4):749\u2013762","journal-title":"Ann Clin Transl Neurol"},{"key":"8218_CR73","doi-asserted-by":"crossref","unstructured":"Yan M, Fu Y, Rao H, Zhou H, Liang X (2021) Expression and clinical significance of miR-146a and tumor necrosis factor receptor-associated factor 6 (TRAF6) in myasthenia gravis patient serum, BioMed Res. Int., vol. 2021","DOI":"10.1155\/2021\/5573469"},{"key":"8218_CR74","unstructured":"Jiang Y et al (2020) Thymic Stromal Lymphopoietin promoted CD4\u2009+\u2009CD25-T cells differentiation isolated from the thymus of patients with Myasthenia Gravis to CD4\u2009+\u2009CD25\u2009+\u2009Regulatory T Cells In Vitro, Preprints,"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08218-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:28:19Z","timestamp":1757165299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08218-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["8218"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08218-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}